title: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
abstract: The FL2000 study was undertaken to evaluate the combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy plus interferon in the first-line treatment of follicular lymphoma patients with a high tumor burden. Patients were randomly assigned to receive either 12 courses of the chemotherapy regimen CHVP (cyclophosphamide, adriamycin, etoposide, and prednisolone) plus interferon-alpha2a (CHVP+I arm) over 18 months or 6 courses of the same chemotherapy regimen combined with 6 infusions of 375 mg/m(2) rituximab and interferon for the same time period (R-CHVP+I arm). After a median follow-up of 5 years, event-free survival estimates were, respectively, 37% (95% confidence interval [CI], 29%-44%) and 53% (95% CI, 45%-60%) in the CHVP+I and R-CHVP+I arm (P = .001). Five-year overall survival estimates were not statistically different in the CHVP+I (79%; 95% CI, 72%-84%) and R-CHVP+I (84%; 95% CI, 78%-84%) arms. In a multivariate regression analysis, event-free survival was significantly influenced by both the Follicular Lymphoma International Prognostic Index score (hazard ratio = 2.08; 95% CI, 1.6%-2.8%) and the treatment arm (hazard ratio = 0.59; 95% CI, 0.44%-0.78%). With a 5-year follow-up, the combination of rituximab with CHVP+I provides superior disease control in follicular lymphoma patients despite a shorter duration of chemotherapy. This study's clinical trial was registered at the National Institutes of Health website as no. NCT00136552.
authors.affiliation: Hospices Civils de Lyon and Université Lyon 1, Lyon, France. gilles.salles@chu-lyon.fr
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Sophie
authors.initials: S
authors.lastname: de Guibert
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
authors.forename: Chantal
authors.initials: C
authors.lastname: Doyen
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Rossi
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.forename: Pauline
authors.initials: P
authors.lastname: Brice
authors.forename: Béatrice
authors.initials: B
authors.lastname: Mahé
authors.forename: Reda
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: Bruno
authors.initials: B
authors.lastname: Audhuy
authors.forename: Christophe
authors.initials: C
authors.lastname: Ferme
authors.forename: Caroline
authors.initials: C
authors.lastname: Dartigeas
authors.forename: Pierre
authors.initials: P
authors.lastname: Feugier
authors.forename: Catherine
authors.initials: C
authors.lastname: Sebban
authors.forename: Luc
authors.initials: L
authors.lastname: Xerri
authors.forename: Charles
authors.initials: C
authors.lastname: Foussard
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide; D004317:Doxorubicin; D005047:Etoposide; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011239:Prednisolone; D011379:Prognosis; D011994:Recombinant Proteins; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000069283:Rituximab; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone